Incannex Healthcare Limited

ASX:IHL.AX

0.04 (AUD) • At close November 21, 2023
Bedrijfsnaam Incannex Healthcare Limited
Symbool IHL.AX
Munteenheid AUD
Prijs 0.041
Beurswaarde 65,067,410
Dividendpercentage 0%
52-weken bereik 0.041 - 0.28
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Joel Bradley Latham
Website https://www.incannex.com.au

An error occurred while fetching data.

Over Incannex Healthcare Limited

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive

Vergelijkbare Aandelen

Sigma Healthcare Limited logo

Sigma Healthcare Limited

SIG.AX

1.27 AUD

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX

4.5 AUD

Estia Health Limited logo

Estia Health Limited

EHE.AX

3.08 AUD

Opthea Limited logo

Opthea Limited

OPT.AX

0.535 AUD

Neuren Pharmaceuticals Limited logo

Neuren Pharmaceuticals Limited

NEU.AX

13.56 AUD

Monash IVF Group Limited logo

Monash IVF Group Limited

MVF.AX

1.145 AUD

Mesoblast Limited logo

Mesoblast Limited

MSB.AX

0.945 AUD

Oceania Healthcare Limited logo

Oceania Healthcare Limited

OCA.AX

0.665 AUD

AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited

AFP.AX

3.2 AUD

Regis Healthcare Limited logo

Regis Healthcare Limited

REG.AX

5.22 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)